Mori Masataka
   Department   University Hospital  General Thoracic Surgery, Clinical Departments
   Position  
Article types journal article
Language English
Peer review Peer reviewed
Title Prognostic factors of advanced or postoperative recurrent non-small cell lung cancer targeted with immune check point inhibitorsPrognostic factors of advanced or
Journal Formal name:Journal: Journal of Thoracic Disease
Domestic / ForeginForegin
Volume, Issue, Page 11(4),1117-1123頁
Author and coauthor Yoshinobu Ichiki, Akihiro Taira, Yasuhiro Chikaishi, Hiroki Matsumiya, Masataka Mori, Masatoshi Kanayama, Yusuke Nabe, Shinji Shinohara, Taiji Kuwata, Masaru Takenaka, Soichi Oka, Ayako Hirai, Naoko Imanishi, Kazue Yoneda, Koji Kuroda, Yoshihisa Fujino, Fumihiro Tanaka
Publication date 2019/04
Summary Background: Although immune checkpoint inhibitors (ICIs) for non-small cell lung cancer (NSCLC)
have been established as one of standard therapy, the prognostic factors of ICIs remain unclear, aside from
the programed cell death-ligand 1 (PD-L1) expression of tumor cells. The aim of this study was to determine
the prognostic factors of ICIs.
Methods: We analyzed the clinicopathological data of 44 cases of advanced NSCLC targeted with ICIs
in our hospital, between February 2016 and February 2018, in order to determine the prognostic factors of
ICIs. We also reviewed the literature regarding ICIs.
Result: We retrospectively analyzed the 44 cases (26 nivolumab and 18 pembrolizumab cases). These
patients were 38 men and 6 women, comprising 13 cases of adenocarcinoma, 29 squamous cell carcinoma
and 2 unclassified types. Seven patients were using first-line therapy and while the others were using secondline
therapy or later. Epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase
(ALK) mutations were negative in all the cases. The response rate and disease control rate were 20.5% and
51.3%, respectively. The median progression-free survival time and median survival time were 146 days and
257 days, respectively. We observed five severe adverse effects (AEs) (three cases of interstitial pneumonia,
one of liver dysfunction and one of adrenal failure), that were resolved by steroid pulse therapy. In
multivariate analyses, the Eastern Cooperative Oncology Group performance status (ECOG PS), pathological
type, standardized uptake value (SUV) on positron emission tomography (PET), white blood cell (WBC)
count, neutrophil, neutrophil-to-lymphocyte ratio (NLR), lactate dehydrogenase (LDH) and albumin were
independently prognostic factors. There were no significant differences in the prognosis between nivolumab
and pembrolizumab.
DOI 10.21037/jtd.2019.04.41